AVE 50.0% 0.3¢ avecho biotechnology limited

Stockwatch 26 March 2012James Wilson - RBS Morgans, Senior...

  1. 2,006 Posts.
    Stockwatch 26 March 2012

    James Wilson - RBS Morgans, Senior Resources Analyst

    Phosphagenics

    A fool not to own it! POH has developed technology which utilises the properties of Vitamin E to transmit drugs across the skin. Using the magic of Vitamin E, applications have been developed to potentially treat chronic pain, dermatology, and animal health conditions. Already a range of skin care products called "Elixia" are available for sale across 600 stockists in Australia, including Myer and David Jones, however, the real jewel in the crown is using the technology to develop a transdermal patch to deliver a regulated dose of oxyocodone to chronic pain sufferers. A major clinical trail is due to start later this year and if successful will be ready for product approval in FY14.

    PT: $0.30 Buy

    Link:http://www.perthnow.com.au/business/stock-watch-april-fools/story-e6frg2qc-1226310625877

    (Yes, all Pohsters know he has some of his facts wrong but it's nevertheless a solid buy recommendation.)
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.